These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 7585497)

  • 1. Tumor growth inhibition mediated by lymphotoxin: evidence of B lymphocyte involvement in the antitumor response.
    Qin Z; Blankenstein T
    Cancer Res; 1995 Nov; 55(21):4747-51. PubMed ID: 7585497
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Involvement of B lymphocytes in the growth inhibition of human pulmonary melanoma metastases in athymic nu/nu mice by an antibody-lymphotoxin fusion protein.
    Reisfeld RA; Gillies SD; Mendelsohn J; Varki NM; Becker JC
    Cancer Res; 1996 Apr; 56(8):1707-12. PubMed ID: 8620479
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alpha 1-interferon gene transfer into metastatic Friend leukemia cells abrogated tumorigenicity in immunocompetent mice: antitumor therapy by means of interferon-producing cells.
    Ferrantini M; Proietti E; Santodonato L; Gabriele L; Peretti M; Plavec I; Meyer F; Kaido T; Gresser I; Belardelli F
    Cancer Res; 1993 Mar; 53(5):1107-12. PubMed ID: 8439955
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor cells engineered to express interleukin-6 exhibit a reduced tumorigenicity depending on the tumor cell model.
    Ledda MF; Adris S; Bravo AI; Bover L; Carbone C; Paleolog E; Mordoh J; Chernajovsky Y; Podhajcer OL
    Cell Mol Biol (Noisy-le-grand); 1996 Jul; 42(5):769-78. PubMed ID: 8832108
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antitumor efficacy of a human interleukin-12 expression plasmid demonstrated in a human peripheral blood leukocyte/human lung tumor xenograft SCID mouse model.
    Hess SD; Egilmez NK; Shiroko J; Bankert RB
    Cancer Gene Ther; 2001 May; 8(5):371-7. PubMed ID: 11477457
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of tumorigenicity and metastasis of human bladder cancer growing in athymic mice by interferon-beta gene therapy results partially from various antiangiogenic effects including endothelial cell apoptosis.
    Izawa JI; Sweeney P; Perrotte P; Kedar D; Dong Z; Slaton JW; Karashima T; Inoue K; Benedict WF; Dinney CP
    Clin Cancer Res; 2002 Apr; 8(4):1258-70. PubMed ID: 11948141
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Secretion of interleukin-10 from murine colon carcinoma cells suppresses systemic antitumor immunity and impairs protective immunity induced against the tumors.
    Kawamura K; Bahar R; Natsume W; Sakiyama S; Tagawa M
    Cancer Gene Ther; 2002 Jan; 9(1):109-15. PubMed ID: 11916240
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Establishment of new SCID and nude mouse models of human B leukemia/lymphoma and effective therapy of the tumors with immunotoxin and monoclonal antibody: marked difference between the SCID and nude mouse models in the antitumor efficacy of monoclonal antibody.
    Kawata A; Yoshida M; Okazaki M; Yokota S; Barcos M; Seon BK
    Cancer Res; 1994 May; 54(10):2688-94. PubMed ID: 8168098
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adenovirus-mediated lymphotactin gene transfer improves therapeutic efficacy of cytosine deaminase suicide gene therapy in established murine colon carcinoma.
    Ju DW; Tao Q; Cheng DS; Zhang W; Zhang M; Hamada H; Cao X
    Gene Ther; 2000 Feb; 7(4):329-38. PubMed ID: 10694814
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adenovirus-mediated interleukin-18 mutant in vivo gene transfer inhibits tumor growth through the induction of T cell immunity and activation of natural killer cell cytotoxicity.
    Hwang KS; Cho WK; Yoo J; Seong YR; Kim BK; Kim S; Im DS
    Cancer Gene Ther; 2004 Jun; 11(6):397-407. PubMed ID: 15044962
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IFN-alpha 1 gene expression into a metastatic murine adenocarcinoma (TS/A) results in CD8+ T cell-mediated tumor rejection and development of antitumor immunity. Comparative studies with IFN-gamma-producing TS/A cells.
    Ferrantini M; Giovarelli M; Modesti A; Musiani P; Modica A; Venditti M; Peretti E; Lollini PL; Nanni P; Forni G
    J Immunol; 1994 Nov; 153(10):4604-15. PubMed ID: 7963533
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Induction of T-cell antitumor immunity and protection against tumor growth by secretion of soluble human CD70 molecules.
    Cormary C; Gonzalez R; Faye JC; Favre G; Tilkin-Mariamé AF
    Cancer Gene Ther; 2004 Jul; 11(7):497-507. PubMed ID: 15153937
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rejection of tumors in mice with severe combined immunodeficiency syndrome determined by the major histocompatibility complex. Class I expression on the graft.
    Glas R; Waldenström M; Höglund P; Klein G; Kärre K; Ljunggren HG
    Cancer Res; 1995 May; 55(9):1911-6. PubMed ID: 7728758
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adenovirus vector-mediated overexpression of a truncated form of the p65 nuclear factor kappa B cDNA in dendritic cells enhances their function resulting in immune-mediated suppression of preexisting murine tumors.
    Lee JM; Mahtabifard A; Yamada R; Crystal RG; Korst RJ
    Clin Cancer Res; 2002 Nov; 8(11):3561-9. PubMed ID: 12429647
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High level expression of the homeobox gene HB24 in a human T-cell line confers the ability to form tumors in nude mice.
    Deguchi Y; Kehrl JH
    Cancer Res; 1993 Jan; 53(2):373-7. PubMed ID: 8093351
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-tumor immunity is involved in the thymidine kinase-mediated killing of tumors induced by activated Ki-ras(G12V).
    Pavlovic J; Nawrath M; Tu R; Heinicke T; Moelling K
    Gene Ther; 1996 Jul; 3(7):635-43. PubMed ID: 8818652
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vaccination with tumor cells engineered to secrete interleukin 2-immunoglobulin G fusion protein induces tumor rejection.
    Bulfone-Paus S; von Bernuth H; Rückert R; Wachtlin J; Ungureanu D; Notter M; Krause H; Pohl T; Paus R; Kunzendorf U
    Cancer Res; 1998 Jul; 58(13):2707-10. PubMed ID: 9661877
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vivo induction of antitumor immunity and protection against tumor growth by injection of CD154-expressing tumor cells.
    Grangeon C; Cormary C; Douin-Echinard V; Favre G; Couderc B; Tilkin-Mariamé AF
    Cancer Gene Ther; 2002 Mar; 9(3):282-8. PubMed ID: 11896445
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Suppression of LNCaP prostate cancer xenograft tumors by a prostate-specific protein tyrosine phosphatase, prostatic acid phosphatase.
    Igawa T; Lin FF; Rao P; Lin MF
    Prostate; 2003 Jun; 55(4):247-58. PubMed ID: 12712404
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro selection of NIH-3T3 cells for resistance to lymphotoxin induces resistance to activated macrophages and enhances tumorigenicity in vivo.
    Totpal K; Lapushin R; Ananthaswamy HN; Aggarwal BB
    Lymphokine Cytokine Res; 1991 Oct; 10(5):359-67. PubMed ID: 1768739
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.